Clinical Trials
36 trialsABBY
Abramson Cancer Center at Penn Medicine
PIKALO-1
Eli Lilly and Company
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Eli Lilly and Company
EVOLVE-BDT
UNC Lineberger Comprehensive Cancer Center
MoonROSE
Genentech, Inc.
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
National Cancer Institute (NCI)
CAROLEEN
Novartis
I-SPY
QuantumLeap Healthcare Collaborative
Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer.
City of Hope Medical Center
VS-6766+Abema+Fulv in Met HR+/HER- BC
Dana-Farber Cancer Institute
ELAINEIII
LeonaBio
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
Icahn School of Medicine at Mount Sinai
ELECTRA
Stemline Therapeutics, Inc.
INX-315-01
Incyclix Bio
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Ellipses Pharma
Morpheus-panBC
Hoffmann-La Roche
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
University of California, Irvine
MiRaDoR
MedSIR
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
Memorial Sloan Kettering Cancer Center
BRE-09
University of Illinois at Chicago
A Phase Ib/II Study to Evaluate Multiple Combination Therapies of FWD1802 in Patients With ER+/HER2- BC
Forward Pharmaceuticals Co., Ltd.
ELEVATE
Stemline Therapeutics, Inc.
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Study of AVZO-021 in Patients With Advanced Solid Tumors
Avenzo Therapeutics, Inc.
RADIANT: Pre-op Radiation With Abemaciclib and Letrozole
Rutgers, The State University of New Jersey
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
Northwestern University
AURA
Japanese Foundation for Cancer Research
ROYAL
Azienda Ospedaliero-Universitaria di Modena
CAMBRIA-2
AstraZeneca
Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
University of Texas Southwestern Medical Center
MINERVA
University of Ulm
Neo-AGILE
Fondazione Oncotech
PALMARES-2
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Rainbow
Fudan University
Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)
Fudan University
ORACLE-RIPA
National Taiwan University Hospital